Blog
RSS FeedPosted by Michael Wonder on 04 Jul 2022
TLV reconsiders Orkambi's subsidy
4 July 2022 - TLV has started a reconsideration of the drug Orkambi in light of the fact that the ...
Posted by Michael Wonder on 02 Jun 2022
TLV reconsiders subsidy of the IL-17 and IL-23 inhibitors
2 June 2022 - The TLV has started a trial for the interleukin 17 and interleukin 23 inhibitors. ...
Posted by Michael Wonder on 18 May 2022
TLV reconsiders subsidy of CGRP inhibitors
18 May 2022 - TLV has started a review of the CGRP inhibitors. ...
Posted by Michael Wonder on 17 Feb 2021
TLV is tasked with reducing costs for medicines
16 February 2021 - The Government has commissioned the Swedish Dental and Pharmaceutical Benefits Agency, TLV, to implement measures to reduce ...
Posted by Michael Wonder on 29 Oct 2020
The regions have applied for a price change for Cimzia and Simponi
29 October 2020 - The regions have submitted an application for a price change for Cimzia (certolizumab pegol) and Simponi (golimumab). ...
Posted by Michael Wonder on 08 Jul 2020
TLV is reviewing the subsidy of SGLT-2 inhibitors
8 July 2020 - TLV has started a review of subsidy restrictions for the SGLT-2 inhibitors. ...
Posted by Michael Wonder on 28 May 2020
TLV has decided to reconsider the subsidy status for certain drugs
26 May 2020 - TLV initiates a review for review of subsidy status for drugs that are part of one ...
Posted by Michael Wonder on 03 Apr 2020
The review shows that it is possible to lower the cost of medicines
3 April 2020 - There are opportunities to make savings on medicines. ...
Posted by Michael Wonder on 28 Jan 2020
TLV is reviewing the subsidy of factor VIII drugs with side agreements
28 January 2020 - Factor VIII drugs are used to treat a form of hemorrhagic disease, hemophilia A, which involves ...
Posted by Michael Wonder on 15 Jan 2020
TLV has decided to reconsider the subsidy for Xeljanz
14 January 2020 - When TLV decided that Xeljanz should be included in the high-cost protection, this was justified by the ...